Highlights of the important and the interesting from the world of healthcare:
Zimmer comes under federal microscope: Often a thorn in the side of the device and drug industries, Iowa Sen. Charles Grassley is reprising the role–and this time the target is Zimmer Holdings. Grassley has asked Indiana-based Zimmer to disclose how it tracked the long-term performance of its orthopedic devices, citing concerns about the alleged failure of its knee and hip replacements.
Defeat for the drug companies (for now): A Senate committee approved legislation to prohibit drug companies from paying generic drug makers to delay bringing less costly products to market. The underlying bill has yet to advance to either the House or Senate floors so this one has a long way to go.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Missouri votes on reform: Missouri primary voters seem likely to pass a ballot measure aimed at invalidating this year’s health reform law, but the measure is likely “meaningless and unconstitutional.”
Thumbs up for Geron: The FDA has given the green light to California-based Geron to proceed with “the world’s first human test of a treatment made from embryonic stem cells,” a study of patients with spinal cord injuries.
ACOs in New Hampshire: New Hampshire has jumped on the accountable care organization trend, starting a pilot program in which about a dozen hospitals will earn compensation based on the quality of the care they provide, rather than on the procedures they perform. Many details of the program remain to be worked out.
Photo from flickr user Biology Big Brother
